Targeted therapies for KRAS-mutant non-small cell lung cancer: from preclinical studies to clinical development—a narrative review

BACKGROUND AND OBJECTIVE: Non-small cell lung cancer (NSCLC) with Kirsten rat sarcoma viral oncogene homolog (KRAS) driver alterations harbors a poor prognosis with standard therapies, including chemotherapy and/or immunotherapy with anti-programmed cell death protein 1 (anti-PD-1) or anti-programme...

Descripción completa

Detalles Bibliográficos
Autores principales: Santarpia, Mariacarmela, Ciappina, Giuliana, Spagnolo, Calogera Claudia, Squeri, Andrea, Passalacqua, Maria Ilenia, Aguilar, Andrés, Gonzalez-Cao, Maria, Giovannetti, Elisa, Silvestris, Nicola, Rosell, Rafael
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989806/
https://www.ncbi.nlm.nih.gov/pubmed/36895930
http://dx.doi.org/10.21037/tlcr-22-639

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9989806/
https://www.ncbi.nlm.nih.gov/pubmed/36895930
http://dx.doi.org/10.21037/tlcr-22-639

Ejemplares similares